Related Experiment Video

Updated: May 19, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Exploiting the MDM2-CK1α protein-protein interface to develop novel biologics that induce UBL-kinase-modification and

Anne-Sophie Huart1, Nicola J MacLaine, Vikram Narayan

  • 1p53 Signal Transduction Group, Edinburgh Cancer Research Centre in the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.

Plos One
|August 24, 2012
PubMed

Insights

Researchers developed a novel peptide biologic targeting the CK1α-MDM2 interaction to control cell growth. This peptide inhibits the interaction, induces cell death, and reveals new insights into protein kinase signaling and cell survival pathways.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Biotechnology

Background:

  • Protein-protein interactions are crucial for cell growth signaling.
  • Casein Kinase 1 alpha (CK1α) interacts with MDM2 oncoprotein, leading to p53 degradation.
  • Inhibiting CK1 or depleting CK1α stabilizes p53, impacting cell death and growth arrest.

Purpose of the Study:

  • To map the CK1α-MDM2 protein-protein interface.
  • To develop novel biologic tools derived from this interface.
  • To investigate the role of the CK1-MDM2 interaction in p53 activation and cell viability.

Main Methods:

  • Screening of overlapping peptides from CK1α for MDM2 binding.
  • Utilized ELISA, cell lysate pull-down, competition ELISA, and ubiquitination assays.
  • Transfection and ectopic expression of a dominant peptide (peptide 35).

Main Results:

  • Identified a dominant peptide (peptide 35) that binds MDM2 and inhibits the CK1α-MDM2 interface.
  • Peptide 35 induced cell death/growth arrest independently of p53.
  • Ectopic expression of peptide 35 induced novel ubiquitin and NEDD8 modification of CK1α.

Conclusions:

  • A specific MDM2 binding motif in CK1α was identified and isolated as a peptide biologic.
  • This peptide acts as a dominant-negative inhibitor, a tool for studying CK1α NEDDylation, and reduces cell growth.
  • This approach offers a blueprint for developing biologics targeting protein-protein interactions in signaling pathways.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...